EUVIMEDEUVIMED entdecken
Crossref

Clinical outcomes after 2‐year follow‐up of transvaginal radiofrequency ablation of symptomatic uterine fibroids

Ángel Santalla-Hernández iD, Mariña Naveiro-Fuentes, María Setefilla López-Criado, Roi Naveiro-Flores iD, Jorge Fernández-Parra

Journal of Obstetrics and Gynaecology Research · 2025

DOI: 10.1111/jog.16216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Ángel Santalla-Hernández und 4 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Gynecology Department, Virgen de las Nieves University Hospital, Granada, Spain. Hauptthemen laut MEDLINE: Leiomyoma, Radiofrequency Ablation, Uterine Neoplasms, Catheter Ablation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The aim of this study was to evaluate the efficacy after 2 years follow‐up of transvaginal radiofrequency ablation (TVRA) to treat myomas, and to identify factors predictive of the response to the treatment.

Methods

This is a prospective cohort study of a 2‐year follow‐up of 65 patients who underwent TVRA for the treatment uterine fibroids at Virgen de las Nieves University Hospital in Granada, Spain. Ultrasound mean fibroid volume, symptom severity scale, total bleeding days, complications, pregnancy outcomes were recorded.

Results

Statistically significant improvements in symptoms and bleeding were observed at 6, 12, and 24 months after the procedure. The mean myoma volume (cc) was significantly lower ( p < 0.05) at 12 and 24 months, with a mean reduction in myoma volume of more than 80% and 60%, respectively. After a 24‐month follow‐up, 5 patients (7.7%) required additional surgical treatment to control symptoms. Patient age (>40 years), initial myoma size, and the timing of radiofrequency were identified as factors related to outcomes in the bivariate analysis.

Conclusions

Transvaginal radiofrequency ablation is an effective and safe technique for the treatment of myomas after 2 years of follow‐up, which improves the symptoms of the patients and decreases the final volume of the myoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeiomyomaRadiofrequency AblationUterine NeoplasmsCatheter AblationHumansFemaleAdultFollow-Up StudiesMiddle AgedProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

abnormal uterine bleedingbenign disease of uterusgynecologic imagingleiomyomas of the uterus

Autor:innen und Institutionen

  • Obstetrics and Gynecology Department, Virgen de las Nieves University Hospital, Granada, Spain.
  • Quantitative Methods Department, Statistical, CUNEF University, Madrid, Spain.

ORCID-Profile: Ángel Santalla-Hernández, Roi Naveiro-Flores

Zitieren

APA

Santalla-Hernández, Á., Naveiro-Fuentes, M., López-Criado, M. S., Naveiro-Flores, R., & Fernández-Parra, J. (2025). Clinical outcomes after 2‐year follow‐up of transvaginal radiofrequency ablation of symptomatic uterine fibroids. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16216

Vancouver

Santalla-Hernández Á, Naveiro-Fuentes M, López-Criado MS, Naveiro-Flores R, Fernández-Parra J. Clinical outcomes after 2‐year follow‐up of transvaginal radiofrequency ablation of symptomatic uterine fibroids. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.16216

BibTeX
@article{SantallaHernndez2025,
  author = {Santalla-Hernández, Ángel and Naveiro-Fuentes, Mariña and López-Criado, María Setefilla and Naveiro-Flores, Roi and Fernández-Parra, Jorge},
  title = {Clinical outcomes after 2‐year follow‐up of transvaginal radiofrequency ablation of symptomatic uterine fibroids},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2025},
  doi = {10.1111/jog.16216}
}
Kostenlos starten →